

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K
Current Report Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934

Date of Report: October 20, 2004

Corgenix Medical Corporation
(Exact Name of registrant as specified in its charter)

Colorado	000-24541	93-1223466
(State or other jurisdiction of incorporation)	Commission File Number)	I.R.S. Employer Identification No.)

12061 Tejon St.
Westminster, Colorado 80234
(Address, including zip code, of principal executive offices)

(303) 457-4345
(Registrant's telephone number including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting Material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 1.01. Entry Into Material Definitive Agreement.

As previously disclosed, Corgenix Medical Corporation (“the Company”) and Genesis Bioventures, Inc. (“Genesis”) agreed to an extension to the existing Amended and Restated Agreement and Plan of Merger (the “Merger Agreement”) between the two companies. The extension has been executed in the form of Amendment No. 1 (the “Amendment”) to the Merger Agreement, a copy of which is filed herewith as Exhibit 2.3.

The Amendment states that if, during the period beginning on October 15, 2004 and ending nine months immediately following the Closing, Genesis Common Stock fails to trade at or above \$0.53 per share for at least twelve (12) trading days in any consecutive twenty (20) trading day period, then an additional Seven Million (7,000,000)

shares of Genesis Common Stock shall be issued to those former holders of shares of the Company's Capital Stock. Section 6.3 of the Merger Agreement is amended to state that Genesis must file the applicable preliminary proxy materials with the SEC as promptly as practicable and, in any case, by November 30, 2004. A new section 9.19 to the Merger Agreement provides that the number of Dissenting Shares of the Company shall not consist of more than twelve and one-half percent (12.5%) of the issued and outstanding shares of Corgenix common stock, excluding shares owned by officers, directors, and Medical & Biological Laboratories Company, Ltd. Section 14.1 of the Merger Agreement is amended to change the date after which the Company or GBI may unilaterally terminate the Merger Agreement if the closing has not yet occurred from July 30, 2004 to February 28, 2005. In addition, the section is further amended to allow the Company to terminate the Merger Agreement at any time prior to November 30, 2004 if it is not satisfied with the terms or the progress of the new equity financing which is a condition to the closing of the Merger pursuant to section 9.13 of the Merger Agreement, or if at any time between October 15, 2004 and November 30, 2004 there shall have been any material adverse change in the financial condition of Genesis.

References to the Merger Agreement and the Amendment are qualified in their entirety to the complete text of such documents filed herewith or previously filed with the Securities and Exchange Commission and incorporated herein by reference.

Capitalized terms used herein and not otherwise defined are used as defined in the Merger Agreement, as amended.

Item 9.01. Financial Statements and Exhibits.

(c) Exhibits

- 2.3 Amendment No. 1 to Amended and Restated Agreement and Plan of Merger

SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

DATED, this 20th day of October, 2004.

Corgenix Medical Corporation
By: /s/ Douglass T. Simpson
Douglass T. Simpson
President